Cyclo(prolylglycyl)

DB04541InvestigationalSmall molecule

NA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy with Atazanavir and Dexamethasone for COVID-19).

Chemical structure of Cyclo(prolylglycyl)
Formula / weight
C7H10N2O2 · 154.1665 g/mol (avg)
Also known as
(S)-Hexahydropyrrolo(1,2-a)pyrazine-1,4-dione-4-17O · Cyclo(pro-gly) · Cyclo(pro-O-gly) · TRANEUROCIN
Code names
NA-831

Resolves to

Compound
UNIIW7O69J5F2BCAS97011-16-0ChEMBLCHEMBL360216ChEBI748694PubChem126154
Structure
InChIKeyOWOHLURDBZHNGG-YFKPBYRVSA-NSMILES[H][C@@]12CCCN1C(=O)CNC2=O
Targets
P11797chiB

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Cyclo(prolylglycyl), and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In